Cost-effectiveness of trastuzumab deruxtecan in previously treated human epidermal growth factor receptor 2-low metastatic breast cancer

BACKGROUND: Results from DESTINY-Breast04 trial revealed that trastuzumab deruxtecan (T-DXd) improved both progression-free survival and overall survival for patients with human epidermal growth factor receptor 2 (HER2)-low metastatic breast cancer (mBC). However, the economic impact of this practic...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Jiangping, Han, Jiaqi, Zeng, Ni, Yan, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204055/
https://www.ncbi.nlm.nih.gov/pubmed/37228255
http://dx.doi.org/10.1177/17588359231169983

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204055/
https://www.ncbi.nlm.nih.gov/pubmed/37228255
http://dx.doi.org/10.1177/17588359231169983

Ejemplares similares